Last reviewed · How we verify
Everolimus Tablets
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation. Used for Advanced renal cell carcinoma, Breast cancer (hormone receptor-positive, HER2-negative), Pancreatic neuroendocrine tumors.
At a glance
| Generic name | Everolimus Tablets |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Drug class | mTOR inhibitor |
| Target | mTOR (mTORC1) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Immunology |
| Phase | FDA-approved |
Mechanism of action
Everolimus is an mTOR inhibitor that suppresses cell cycle progression and angiogenesis by blocking the mTORC1 signaling pathway. This leads to reduced cell proliferation and increased apoptosis in cancer cells. It is also used as an immunosuppressant to prevent organ rejection by inhibiting T-cell activation.
Approved indications
- Advanced renal cell carcinoma
- Breast cancer (hormone receptor-positive, HER2-negative)
- Pancreatic neuroendocrine tumors
- Subependymal giant cell astrocytoma (SEGA)
- Organ transplant rejection prevention
Common side effects
- Stomatitis/mouth ulcers
- Infections
- Rash
- Diarrhea
- Fatigue
- Anemia
- Hyperglycemia
- Hyperlipidemia
- Pneumonitis
Key clinical trials
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (PHASE2, PHASE3)
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (PHASE2)
- Everolimus Trial in Laryngotracheal Stenosis (EARLY_PHASE1)
- Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) (PHASE1, PHASE2)
- Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) (PHASE2)
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (PHASE2)
- Rapalog Pharmacology (RAP PAC) Study (PHASE1)
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Everolimus Tablets CI brief — competitive landscape report
- Everolimus Tablets updates RSS · CI watch RSS
- Shandong Suncadia Medicine Co., Ltd. portfolio CI